Subacute thyroiditis (SAT), also called de Quervain thyroiditis or granulomatous thyroiditis, is a self-limiting, possibly viral, and inflammatory thyroid disorder that is usually associated with thyroid pain and systemic symptoms. This report details a case of SAT possibly associated with influenza vaccine (Vaxigrip®) in a young female. The diagnosis, therapeutic management and outcome are discussed.

Key Words: subacute thyroiditis, de Quervain thyroiditis, influenza vaccine

CASE REPORT

A 25-year-old female suffering from fever, left neck swelling, and tender bulging mass for 3 days visited our clinic. Her body temperature ranged from 37 to 39°C. There were no chills, sore throat, cough, shortness of breath or chest pain, and no genitourinary symptoms. Two days before this episode of fever and subsequent development of a small, tender bulging neck mass, which progressively enlarged, she had received an influenza vaccine injection of Vaxigrip®. Tracing back her history, she had experienced the same symptoms when she was 12 years old and recovered spontaneously. Therefore, we strongly suspected that SAT was possibly associated with influenza vaccine (Vaxigrip®) in this case.
4,000–11,000/μL and C-reactive protein level was 14 μg/mL (normal, <5 μg/mL). Urinalysis showed normal results.

Blood culture results were negative. Thyroid function test results were normal (total T4, 8.2 μg/dL; total T3, 85 ng/dL; TSH, 1.0 μU/mL). Microsomal and thyroglobulin antibody test results were negative. Thyroid echocardiography showed a hypoechoogenic area over the left lobe (Figure 1). Multinuclear giant cell granulomas were observed in a fine-needle aspiration biopsy of the thyroid (Figure 2). The patient became afebrile during the next week, while receiving nonsteroidal anti-inflammatory drugs and steroids and recovered 2 weeks later. The tender neck mass also disappeared. According to the clinical manifestations, SAT was diagnosed. Since there was no viral infection prior to this episode and fever had occurred just after influenza vaccination, we suspected that this episode of SAT was associated with the administration of influenza vaccine.

**DISCUSSION**

SAT has been termed granulomatous giant cell or de Quervain’s thyroiditis. It is characterized by a generally self-limiting, usually painful inflammatory lesion of the thyroid gland, most probably of viral origin [5]. Many viruses have been implicated, including mumps, Coxsackie, influenza, adenoviruses, and echoviruses [6–8]. All current evidence indicate that SAT is not an autoimmune disease. The peak incidence occurs at 30–50 years of age, and women are affected thrice more frequently than men [3,9].

SAT begins with a prodrome of generalized myalgias, pharyngitis, low-grade fever and fatigue. Patients then present with fever and severe neck pain, swelling, or both. Painful SAT, which is a self-limiting inflammatory disorder, is the most common cause of thyroid pain [10]. A viral cause of SAT has, therefore, been proposed, but clear evidence is still lacking [7].

The hallmark of painful SAT is a markedly elevated erythrocyte sedimentation rate. C-reactive protein concentration is similarly elevated [11]. Color-flow Doppler ultrasonography may also help to make this distinction; in patients with Graves’ disease, the thyroid gland is hyper-vascular, whereas in patients with painful SAT, the gland is hypoechoogenic and has low-to-normal vascularity [12]. The treatment for painful SAT is to provide symptomatic relief only. Nonsteroidal medications or salicylates are adequate to control mild thyroid pain; high doses of glucocorticoids (e.g. 40 mg/day prednisone) provide immediate relief. The doses of steroid should be tapered over a period of 4–6 weeks [13].

SAT, which is considered to be a viral disease [6–8], rarely recurs after a complete recovery, possibly because of immunity to the offending virus. However, late recurrence after several years has been reported [14–17]. The recurrent episodes were similar to the first episode of SAT. The titers of various viral antibodies were not increased during the clinical course of recurrence [17].

If vaccination is performed with heterologous antigens that are sufficiently different to permit an immunologic response, but are sufficiently similar to react with autologous antigens, then the vaccinated antigen may induce various immune response and systemic symptoms such as fever and myalgia. We report in this case that SAT occurred just after influenza vaccination and without a recent episode of viral infection before SAT. The patient had experienced a similar episode of fever and tender neck mass at 12 years of age, so SAT could be a possible diagnosis for that episode.
The recurrent episode is thought possibly to have been induced by the influenza vaccine injection due to delayed hypersensitivity reactions with sensitized lymphoid cells.

The side effects of and adverse reactions to influenza vaccine (Vaxigrip®) [18,19] that occurred during clinical trials were erythema, redness, swelling, pain, ecchymosis and induration. The most frequent side effect of vaccination is soreness at the vaccination site (affecting 10–64% patients) that lasts < 2 days. Systemic reactions included fever, malaise, myalgia, headache, shivering, sweating, muscular pain and joint pain. These reactions begin 6–12 hours after vaccination and can persist for 1–2 days. No clinical case report to date has demonstrated an association between SAT and influenza vaccination.

In the Minnesota cohort study [20], the inclusion criteria for diagnosis of SAT were any one of the following: (1) painful thyroid and either suppressed uptake of 131I or elevated erythrocyte sedimentation rate, or both; (2) unilateral thyroid pain with normally low uptake of 131I and elevated erythrocyte sedimentation rate; and (3) pathologic diagnosis (surgical specimen or biopsy). In our case, the patient presented with fever, left neck swelling, and tender bulging mass. In addition, markedly elevated erythrocyte sedimentation rate was observed. These findings were consistent with a diagnosis of SAT. As there was no evidence of recent bacterial or viral infection prior to this episode and because fever had occurred just after influenza vaccination, we highly suspected this episode of SAT to be directly associated with the influenza vaccine or that the recurrence was aggravated by influenza vaccination, but direct association with the influenza vaccine is not confirmed.

This case was a rare clinical case. Other researchers [21, 22] compiled and analyzed safety data on the inactivated split influenza vaccine, Vaxigrip®, from 28 clinical trials (total: 4,599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent solicited reactions were noneverse injection site pain and erythema in children, adults and the elderly. Mild or moderate fever was the most frequent reaction among 6- to 36-month-old individuals; few systemic reactions were reported in older groups. Reactogenicity was comparable in healthy and high-risk children. The long-term experience with the world’s most widely used influenza vaccine, Vaxigrip®, confirms its excellent tolerability, and its continued use in clinical practice worldwide is supported.

REFERENCES
接種流行性感冒疫苗之後引發
亞急性甲狀腺炎的一位成人病例報告

蕭政岳  辛世杰  謝明家  蕭璧容  辛錫璋
高雄醫學大學附設中和紀念醫院 內分泌暨新陳代謝內科

亞急性甲狀腺炎（又稱為 de Quervain 甲狀腺炎或肉芽性甲狀腺炎）是一種
會自癒的病毒性或發炎性甲狀腺疾病，通常會以甲狀腺疼痛和全身性症狀來表現。
這病例報告是描述一位年輕女性的亞急性甲狀腺炎可能與注射流行性感冒疫苗
有關，這病例的診斷，治療處理和結果將被討論。

關鍵詞：亞急性甲狀腺炎，de Quervain 甲狀腺炎，流行性感冒疫苗
（高雄醫誌 2006;22:297—300）